CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -

Similar documents
2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,

2. Is the request for Humatrope? Y N [If no, skip to question 6.]

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

First Name. Specialty: Fax. First Name DOB: Duration:

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only

Growth Hormones DRUG.00009

Request for Prior Authorization Growth Hormone (Norditropin

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents

Cigna Drug and Biologic Coverage Policy

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products

The development of a manageable medical

General Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)

HUMAN GROWTH HORMONE GENOTROPIN

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen

Aetna Better Health of Virginia

GROWTH HORMONE THERAPY

Growth Hormone Therapy

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY

PHARMACY POLICY STATEMENT Indiana Medicaid

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen

PHARMACY POLICY STATEMENT Indiana Medicaid

Pharmacy Prior Authorization Growth Hormone- Clinical Guidelines

2. Does the member have a diagnosis of central precocious puberty? Y N

Growth Hormone!gents. WA.PHAR.50 Growth Hormone Agents

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton

Original Effective Date: 7/5/2007

PedsCases Podcast Scripts

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

Pharmacy Management Drug Policy

Cigna Drug and Biologic Coverage Policy

ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)

AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents

Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: Last Review Date:

3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT

Original Effective Date: 7/5/2007

Diagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

DISCLAIMER SUMMARY OF EVIDENCE/POSITION

3. Has the member received the requested drug for less than 2 years? Y N

1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

3. Has the member received the requested drug for less than 2 years? Y N

Growth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives

ORILISSA (elagolix) oral tablet

Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka

MEDICAL POLICY I. POLICY HUMAN GROWTH HORMONE MP POLICY TITLE POLICY NUMBER

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 4/1/19 SECTION: DRUGS LAST REVIEW DATE: 2/21/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Endocrine part two. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy

a. Childhood onset: secondary to Any of the following causes: the term Growth Hormone Deficiency.

Clinical Policy: Somatropin (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17

How to approach a child with growth concern

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

UW MEDICINE PATIENT EDUCATION. Acromegaly Symptoms and treatments. What is acromegaly? DRAFT. What are the symptoms? How is it diagnosed?

Request for Special Authorization Enbrel

Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A

Medical and Rehabilitation Innovations Neuroendocrine Screening and Hormone Replacement Therapy in Trauma Related Acquired Brain Injury

Home Delivery Pharmacy Program. mycigna.com k 1/07

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?

Growth and Puberty: A clinical approach. Dr Esko Wiltshire

XATMEP (methotrexate) oral solution

Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D.

The Stimulation Test. What, Why, and How. Date. Time. Place. Dr./Nurse. Phone _elhmtp_HG64712_stim_br_fa3.indd 3

Human Biochemistry. Hormones

Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None

2. Is the patient responding to Remicade therapy? Y N

APIDRA (insulin glulisine) injection vial APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector

Original Article Pituitary imaging in 129 children with growth hormone deficiency: A spectrum of findings

Prior Authorization Criteria Update: Androgens, Topical and Parenteral

Effective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria

PITUITARY: JUST THE BASICS PART 2 THE PATIENT

Corporate Medical Policy

Growth Hormone Deficiency and Related Diagnoses

Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION

Puberty and Pubertal Disorders Part 3: Delayed Puberty

Hypothalamus & Pituitary Gland

What we will cover. Evaluation of the Child with Suspected Pituitary Disease. ituitary

LEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector

Pharmacy Prior Authorization

3. Is the prescribed dose within the Food and Drug Administration (FDA)- approved dosing for giant cell arteritis?

FLUOXETINE 60 MG oral tablet FLUOXETINE 90 MG oral delayed release (once weekly) capsule

Patient Registration Form

BLOOD GLUCOSE METER TEST STRIP STEP THERAPY CRITERIA

Drug Prior Authorization Form Opdivo (nivolumab)

SAMPLE IgE: ESR: CRP: # Joints: %BSA: Height: Weight: BMI:

3. Does the patient continue to receive nutritional or psychological counseling? Y N

LOKELMA (sodium zirconium cyclosilicate) oral suspension

Transcription:

Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed processing or an adverse determination for insufficient information. * Provider Name: Specialty: PROVIDER INFORMATION * DEA or TIN: PATIENT INFORMATION **Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed** Office Contact Person: * Patient Name: Office Phone: * CIGNA ID: Office Fax: * Date Of Birth: * Is your fax machine kept in a secure location? * May we fax our response to your office? * Patient Street Address: Office Street Address: City State Zip City State Zip Patient Phone: Medication requested: Medication name: Strength: Dose (mg/kg): Frequency of administration: Patient s current weight: Where will this medication be obtained? CIGNA Tel-Drug (CIGNA's nationally preferred specialty pharmacy) Retail pharmacy Prescriber s office stock (billing on a medical claim form) Home Health / Home Infusion vendor Please specify the following: Has this patient been treated with growth hormone in the past? If Yes, what was the patient s pre-treatment age? If Yes, what date was growth hormone therapy started? Questions for Pediatric Patients (for Adult patients, see page 4 of this form) Has this patient been evaluated by an endocrinologist (initially and annually)? What was the patient s pre-treatment height? What was the patient s pre-treatment height velocity Are the patient s epiphyses open? CIGNA HealthCare Prior Authorization Form Growth Hormone Medications Page 1 of 5

Growth Hormone Deficiency in Children Does this patient have any of the following CNS pathology? Please check any options that apply: Hypoplasia of pituitary gland Empty sella syndrome Craniofacial developmental defects Septo-optic dysplasia Interruption of pituitary stalk Pituitary or hypothalamic tumors History of irradiation Multiple pituitary hormone deficiency Proven genetic defect affect growth hormone axis Has this patient had a growth hormone response of less than 10ng/mL to at least TWO provocative stimuli? Please note that only 1 stim test is required for children with CNS pathology. Which provocative stimuli tests were performed? Please specify the date and lab value of tests performed. Insulin Stimuli Lab Value Date Taken Levodopa L-Arginine Clonidine Glucagon Have other pituitary hormone deficiencies been ruled out or corrected (including thyroid, cortisol and sex hormones)? Small for Gestational Age Please attach growth curve charts and include all lab levels. What was this patient s gestational age? What was this patient s birth weight? What was this patient s birth length? What was this patient s height at age 2? Please attach growth curve charts. Growth Delay Secondary to Chronic Kidney Disease Does this patient have renal function at stage 2 chronic kidney disease (or GFR from 60-89 ml/min/1.73m 2 )? Please attach growth curve charts. CIGNA HealthCare Prior Authorization Form Growth Hormone Medications Page 2 of 5

Turner s Syndrome Has the diagnosis of Turner s Syndrome been established by genetic testing? Yes No Please note that documentation of genetic testing is required for review of this request. Please attach growth curve charts and documentation of genetic testing. Panhypopituitarism Which of the following anterior pituitary hormones are absent in this patient? Please mark all that apply. Luteinizing Hormone (LH) Follicle Stimulating Hormone (FSH) Thyroid Stimulating Hormone (TSH) Androcorticotropic Hormone Which hormones are being supplemented? Prader-Willi Syndrome Please attach chart notes with lab levels. Has the diagnosis of Prader-Willi Syndrome been confirmed by appropriate genetic testing? Please attach growth curve charts and include all lab levels. Noonan Syndrome Has the diagnosis of Noonan s syndrome been established by genetic testing or in consultation with a geneticist? Please attach growth curve charts. Other Diagnosis (please specify below) What is the patient s diagnosis? (Check all that apply) Crohn s disease Down Syndrome Idiopathic Short Stature of Unknown Origin Intrauterine Growth Restriction (IUGR) Juvenile Rheumatoid Arthritis Non-Growth Hormone Deficient Short Stature Osteogenesis imperfecta Precocious puberty Russell-Silver Syndrome Skeletal dysplasia, such as achondroplasia CIGNA HealthCare Prior Authorization Form Growth Hormone Medications Page 3 of 5

Questions for Adult Patients Adult Growth Hormone Deficiency Has this patient been evaluated by an endocrinologist? Is this patient s growth hormone deficiency a result of documented childhood growth hormone deficiency? Is this patient s growth hormone deficiency a result of any of the following conditions? (Mark all that apply) Destructive hypothalamic disease Destructive pituitary disease Radiation therapy Surgery (please provide details about the procedure) Trauma (please provide details about the nature of trauma) Has this patient had a growth hormone response of less than 5ng/mL to at least ONE provocative stimulus? Which provocative stimuli tests were performed? Please specify the date and lab value of tests performed. Insulin Stimuli Lab Value Date Taken Levodopa L-Arginine Clonidine Glucagon Arginine-GHRH Have other pituitary hormone deficiencies (thyroid, cortisol and sex hormones) been ruled out or corrected? Please attach chart notes with lab values. Multiple Pituitary Hormone Deficiencies / Panhypopituitarism Has this patient been evaluated by an endocrinologist? Which of the following anterior pituitary hormones are absent in this patient? Please mark all that apply. Luteinizing Hormone (LH) Follicle Stimulating Hormone (FSH) Thyroid Stimulating Hormone (TSH) Androcorticotropic Hormone Please attach chart notes with lab values and details of hormonal replacement therapy. CIGNA HealthCare Prior Authorization Form Growth Hormone Medications Page 4 of 5

AIDS Wasting (Serostim Only) What was the patient s pre-treatment baseline body weight? What is the patient s current body weight? What is the patient s current body mass index? Has this patient had failure to treatment with, or contraindication or intolerance to appetite stimulants and/or other anabolic agents? (Please provide medication details in the Details section.) Will this patient have continuous use of antiviral therapy? Short Bowel Syndrome (Zorbtive Only) Please attach chart notes with lab values. Will this medication be used with a special diet AND glutamine supplementation? Is this patient dependant on intravenous parenteral nutrition? Please attach chart notes supporting this request. Other Diagnosis (please specify below) What is the patient s diagnosis? (Check all that apply) Crohn s Disease Increased Athletic Performance Infertility Muscular Dystrophy Obesity Osteoporosis Somatopause CIGNA HealthCare s coverage position on this and other medications may be viewed online at: http://www.cigna.com/customer_care/healthcare_professional/coverage_positions Please fax completed form to (800)390-9745. Due to the clinical information required, requests for Growth Hormone medications cannot be accepted via phone. Our standard response time for prescription drug coverage requests is 2-4 business days. If your request is urgent, it is important that you call Pharmacy Services to have the request expedited. View our formulary on line at http://www.cigna.com. CIGNA Pharmacy Management or CIGNA HealthCare refer to various operating subsidiaries of CIGNA Corporation. Products and services are provided by these subsidiaries and not by CIGNA Corporation. These subsidiaries include Connecticut General Life Insurance Company, Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of CIGNA Health Corporation. V 042910 CIGNA HealthCare Prior Authorization Form Growth Hormone Medications Page 5 of 5